File:11523 2022 944 Fig1 HTML.jpg
Jump to navigation
Jump to search
No higher resolution available.
11523_2022_944_Fig1_HTML.jpg (674 × 240 pixels, file size: 53 KB, MIME type: image/jpeg)
Summary
| Description |
English: Trial design of the randomized, open-label, active-controlled phase III HERO trial in patients with advanced prostate cancer [12]. The primary endpoint of the trial was the sustained castration rate (defined as the cumulative probability of testosterone suppression to < 50 ng/dL) from day 29 through 48 weeks. Efficacy results are reported in the animated figure (available online). BGD between-group difference, mo months, pts patients |
| Date | |
| Source | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198864/ |
| Author | Matt Shirley |
Licensing
English: This file is licensed CC BY-NC 4.0
This file was uploaded with UploadWizard.
File history
Click on a date/time to view the file as it appeared at that time.
| Date/Time | Thumbnail | Dimensions | User | Comment | |
|---|---|---|---|---|---|
| current | 19:29, 5 March 2024 | | 674 × 240 (53 KB) | Ozzie10aaaa (talk | contribs) | Uploaded a work by Matt Shirley from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198864/ with UploadWizard |
You cannot overwrite this file.
File usage
There are no pages that use this file.
